Lipoprotein apheresis: present and future uses

Current Opinion in Lipidology
Patrick M Moriarty

Abstract

For the past 40 years, apheresis, in particular, lipoprotein apheresis, has been the therapy of choice to lower LDL-C for familial hypercholesterolemia patients with uncontrolled dyslipidemia and cardiovascular disease. With the advent of recent and future lipid-modifying agents and their ability to lower LDL-C, the question arises on what will be the future of lipoprotein apheresis. Lipoprotein apheresis lowers not only plasma levels of apolipoprotein B lipoproteins but also markers of vascular inflammation and blood rheology. Other vascular diseases, not necessarily associated with familial hypercholesterolemia, such as nephrotic syndrome and peripheral arterial disease have profited from lipoprotein apheresis therapy. In 2013, the Food and Drug Administration approved lipoprotein apheresis therapy for patients with focal segmental glomerulosclerosis. Since 2010, the German healthcare ministry has approved lipoprotein apheresis therapy for patients with an elevated lipoprotein(a) and ongoing cardiovascular disease irrespective of LDL-C levels. Recent and future lipid-modifying therapies will most likely reduce the practice of lipoprotein apheresis therapy for familial hypercholesterolemia patients. Future implications for lip...Continue Reading

References

Aug 1, 1997·Laryngo- rhino- otologie·M SuckfüllK Schorn
May 5, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·T Yamamoto, T Yamashita
Dec 5, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Motoshi HattoriKatsumi Ito
Jul 5, 2006·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Shuzo KobayashiTakayasu Ohtake
Sep 15, 2007·Medicinski pregled·Biljana Vucković, Mirjana Derić
Oct 24, 2007·The American Journal of Cardiology·Isaac O OpolePatrick M Moriarty
Feb 24, 2009·Nature Clinical Practice. Cardiovascular Medicine·Beate R JaegerUNKNOWN Group of Clinical Investigators
Dec 1, 2009·Clinics in Geriatric Medicine·Ali Yazdanyar, Anne B Newman
Dec 25, 2009·The New England Journal of Medicine·Robert ClarkeUNKNOWN PROCARDIS Consortium
May 5, 2010·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Rachel P SoslandPatrick M Moriarty
Jul 2, 2010·Mayo Clinic Proceedings·Jeffrey W Olin, Brett A Sealove
Apr 25, 2012·Clinical Research in Cardiology Supplements·Volker SchettlerUNKNOWN German Apheresis Working Group
May 26, 2012·Journal of Lipid Research·Kiyohito AraiSotirios Tsimikas
Sep 12, 2012·Current Opinion in Lipidology·Carlos ZaragozaMarta Saura
Sep 22, 2012·Journal of the American Society of Nephrology : JASN·Stephen M Korbet
Sep 25, 2012·Journal of Internal Medicine·F Kronenberg, G Utermann
Jan 30, 2013·Atherosclerosis. Supplements·M BlahaL Sobotka
Mar 20, 2013·Journal of Lipid Research·Kristian TvetenTrond P Leren
Apr 5, 2013·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Kouichi TamuraSatoshi Umemura
Apr 30, 2013·Seminars in Thrombosis and Hemostasis·Biagio BarbanoRosario Cianci
Feb 7, 2014·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Yumiko YuasaMariko Harada-Shiba
Feb 19, 2014·Clinical and Experimental Nephrology·Eri Muso
Apr 17, 2014·Journal of Cardiovascular Pharmacology and Therapeutics·Antonio M GottoUNKNOWN DEFINE Investigators
Jul 9, 2014·Annals of Vascular Diseases
Aug 15, 2014·Journal of Lipid Research·Katherine D ConnollyPhilip E James
Oct 4, 2014·Journal of the American College of Cardiology·Diederik F van WijkErik S G Stroes

❮ Previous
Next ❯

Citations

Feb 20, 2016·Journal of Clinical Lipidology·Harold E BaysTerry A Jacobson
Mar 30, 2017·European Journal of Preventive Cardiology·Paolo RubbaGiuliana Fortunato
Apr 30, 2017·European Heart Journal·Arnold von Eckardstein
Nov 30, 2019·Journal of Clinical Apheresis·Randolf HardersenAnders Hovland
May 24, 2016·Current Opinion in Lipidology·Sergei N PokrovskyMarat V Ezhov
Jul 18, 2018·American Journal of Hypertension·Bruce S Sachais, Beth H Shaz
Jul 16, 2019·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Pankaj HariWilliam E Smoyer
Sep 19, 2020·Current Atherosclerosis Reports·Sergei N PokrovskyMarat V Ezhov

❮ Previous
Next ❯

Methods Mentioned

BETA
rheology

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Current Treatment Options in Cardiovascular Medicine
Patrick M Moriarty
© 2022 Meta ULC. All rights reserved